Top-News
  • Depot
  • Watchlist
  • Glocke

  • Innovent Biologics Inc.

    49,7095 $ +3,2795 $ +7,06%
    In : 42,692 € | 10.09.25 19:16:10 Nasdaq OTC Other aktualisieren | Orderbuch | Mehr Kurse »
    ISIN: US45783L1017
    US-Symbol: IVBIY

    Innovent Biologics Inc. News

    19.09.25 - PR Newswire
    Innovent Announces Mazdutide Received Approval from China's NMPA for Glycemic Control in Adults with Type 2 Diabetes
    Innovent Announces Mazdutide Received Approval from China's NMPA for Glycemic Control in Adults with Type 2 Diabetes PR Newswire
    18.09.25 - PR Newswire
    Innovent's Partner Ollin Announces Clinical Updates on IBI324 (OLN324, VEGF/ANG-2)
    Innovent's Partner Ollin Announces Clinical Updates on IBI324 (OLN324, VEGF/ANG-2) PR Newswire
    15.09.25 - PR Newswire
    Innovent to Present Multiple R&D Results of General Biomedicine Pipeline at the 34th EADV Congress 2025
    Innovent to Present Multiple R&D Results of General Biomedicine Pipeline at the 34th EADV Congress 2025 PR Newswire
    07.09.25 - PR Newswire
    Innovent Announces Phase 2 Results of Tigulixostat (IBI128, XOI) in Gout Patients were Published at the 27th Asia-Pacific League of Associations for Rheumatology Congress
    Innovent Announces Phase 2 Results of Tigulixostat (IBI128, XOI) in Gout Patients were Published at the 27th Asia-​Pacific League of Associations for Rheumatology Congress PR ...
    27.08.25 - PR Newswire
    Innovent Announces 2025 Interim Results and Business Updates
    Innovent Announces 2025 Interim Results and Business Updates PR Newswire
    24.08.25 - PR Newswire
    Innovent Biologics Announces U.S. FDA IND Approval for the First Global MRCT Phase 3 Study (MarsLight-11) of IBI363 (PD-1/IL-2α-bias) in Squamous Non-Small Cell Lung Cancer
    Innovent Biologics Announces U.S. FDA IND Approval for the First Global MRCT Phase 3 Study (MarsLight-11) of IBI363 (PD-1/IL-2α-bias) in Squamous Non-Small Cell Lung Cancer ...
    04.08.25 - PR Newswire
    Innovent Receives U.S. FDA Approval for IND Application of Oral GLP-1R Agonist IBI3032
    Innovent Receives U.S. FDA Approval for IND Application of Oral GLP-1R Agonist IBI3032 PR Newswire
    16.07.25 - PR Newswire
    Nature Medicine Published Phase 1 Results of Innovent Biologics' Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
    Nature Medicine Published Phase 1 Results of Innovent Biologics' Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma PR ...
    30.06.25 - PR Newswire
    Innovent Biologics Showcases "Dual Innovations" at Oncology R&D Day, Pioneering the Future of Cancer Treatment with Next-Generation IO and ADC Platforms
    Innovent Biologics Showcases "Dual Innovations" at Oncology R&D Day, Pioneering the Future of Cancer Treatment with Next-​Generation IO and ADC Platforms PR Newswire
    27.06.25 - PR Newswire
    Innovent Announces Mazdutide, First Dual GCG/GLP-1 Receptor Agonist, Received Approval from China's NMPA for Chronic Weight Management
    Innovent Announces Mazdutide, First Dual GCG/GLP-1 Receptor Agonist, Received Approval from China's NMPA for Chronic Weight Management PR Newswire
    24.06.25 - PR Newswire
    Innovent announces the Phase 3 Clinical Study DREAMS-1 of Mazdutide in China were Orally Presented at ADA 85th Scientific Sessions
    Innovent announces the Phase 3 Clinical Study DREAMS-1 of Mazdutide in China were Orally Presented at ADA 85th Scientific Sessions PR Newswire
    21.06.25 - PR Newswire
    Multiple Research Results from Innovent's General Biomedicine Pipeline to be Showcased at the ADA 85th Scientific Sessions
    Multiple Research Results from Innovent's General Biomedicine Pipeline to be Showcased at the ADA 85th Scientific Sessions PR Newswire
    15.06.25 - PR Newswire
    /C O R R E C T I O N -- Innovent Biologics/
    /C O R R E C T I O N -- Innovent Biologics/ PR Newswire
    12.06.25 - PR Newswire
    Innovent to Present Multiple R&D Results of General Biomedicine Pipeline at the ADA's 85th Scientific Sessions
    Innovent to Present Multiple R&D Results of General Biomedicine Pipeline at the ADA's 85th Scientific Sessions PR Newswire
    04.06.25 - PR Newswire
    Innovent's IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) Receives Second NMPA Breakthrough Therapy Designation for Immuno-resistant Squamous Non-Small Cell Lung Cancer
    Innovent's IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) Receives Second NMPA Breakthrough Therapy Designation for Immuno-​resistant Squamous Non-Small Cell ...
    03.06.25 - PR Newswire
    2025 ASCO Oral Presentation: Innovent Biologics Announces Updated Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) from the Phase 1 PoC Clinical Study in Advanced Non-small Cell Lung Cancer
    2025 ASCO Oral Presentation: Innovent Biologics Announces Updated Data of IBI363 (First-​in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) from the Phase 1 PoC ...
    02.06.25 - PR Newswire
    2025 ASCO Presentation: Innovent Biologics Announces Updated Data of IBI354 (Novel anti-HER2 ADC) From the Phase 1/2 Clinical Study in Advanced Ovarian Cancer, Breast Cancer and Other Solid Tumors
    2025 ASCO Presentation: Innovent Biologics Announces Updated Data of IBI354 (Novel anti-HER2 ADC) From the Phase 1/2 Clinical Study in Advanced Ovarian Cancer, Breast ...
    02.06.25 - PR Newswire
    ASCO 2025 Oral Presentation: Innovent Biologics Announces Updated Data of IBI343 (Novel Anti-CLDN18.2 ADC) From the Phase 1 Clinical Study in Patients with Advanced Pancreatic Cancer
    ASCO 2025 Oral Presentation: Innovent Biologics Announces Updated Data of IBI343 (Novel Anti-CLDN18.2 ADC) From the Phase 1 Clinical Study in Patients with Advanced ...
    01.06.25 - PR Newswire
    2025 ASCO Oral Presentation: Innovent Biologics Announces Updated Date of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) from Phase 1 Clinical Studies in Advanced Colorectal Cancer
    2025 ASCO Oral Presentation: Innovent Biologics Announces Updated Date of IBI363 (First-​in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) from Phase 1 Clinical ...
    31.05.25 - PR Newswire
    ASCO 2025 Oral Presentation: Innovent Biologics Announces Updated Data of IBI363 (First-in-class PD-1/IL-2α -bias Bispecific Antibody Fusion Protein) from Phase 1 and 2 Clinical Studies on Immunotherapy-treated Advanced Malignant Melanoma
    ASCO 2025 Oral Presentation: Innovent Biologics Announces Updated Data of IBI363 (First-​in-class PD-1/IL-2α -bias Bispecific Antibody Fusion Protein) from Phase 1 and 2 Clinical ...

    Newssuche

    Videos

    newspaper
    18:20 Uhr
    Master the Trading!
    In diesem Trading-​Webinar haben wir von A bis Z den Aufbau professionellen Tradings thematisiert und ... Mehr »